Mylan: Teva's stake buy violates U.S. anti-trust rules
Article continues below
"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.
Teva disclosed a 1.35 percent stake in Mylan last week. Mylan did not clarify which anti-trust rule Teva violated.
Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion. ■